The herpesvirus saimiri (HVS) genome has the capacity to incorporate large amounts of heterologous DNA and can be maintained episomally in many different human cell types. To evaluate the efficacy of HVS-mediated gene transfer into human hemopoietic cells, we investigated the ability of an HVS-based construct, carrying the enhanced green fluorescent protein (EGFP) and neomycin resistance genes, to transduce a variety of human hemopoietic cell lines and primary CD34 ϩ cells. As measured by flow cytometry, the numbers of EGFP ϩ cells at 2 days postinfection differed between various cell types ranging, from 1.3% for KG1 cells to 56.8%
H igh-dose chemotherapy followed by peripheral blood progenitor cell transplantation is a potentially curative treatment option for patients with both hematological malignancies and solid tumors. However, there is strong evidence that minimal residual disease persists after high-dose chemotherapy in a number of patients, eventually resulting in disease recurrence. 1 Therefore, several approaches to the treatment of minimal residual disease are currently being evaluated, including treatment with dendritic cell (DC)-based cancer vaccines. 2 DCs, which play a crucial role with regard to the initiation of T-lymphocyte responses, can be generated ex vivo either from CD34 ϩ hematopoietic progenitor cells or from blood monocytes. They can be pulsed in vitro with tumor-derived peptides or proteins and then used as a professional antigen (Ag)-presenting cell vaccine for the induction of Ag-specific T lymphocytes in vivo. Gene therapy vectors can also be used to deliver DNA sequences encoding tumor Ags to DCs, or alternatively to deliver their precursors on the condition that the transgene exists as a stable component of the transduced cell on division.
A number of viral vector systems are currently being developed for gene delivery to hemopoietic progenitors, the majority of which integrate into the genome of the target cell. Retroviruses are the most widely studied of the current generation, but suffer from an inherent incapacity to transduce nondividing cells. In addition, because integration of the retrovirus genome occurs in a random fashion, there is also a possibility of insertional mutagenesis or oncogene activation. 3 Lentivirus vectors, based on HIV, have recently been proposed as an alternative because they are capable of infecting quiescent cells. 4 Adeno-associated virus (AAV) vectors have been used to efficiently transduce a variety of cell types of the hemopoietic system. 5 After transduction, AAVs can either integrate into the host chromosome or exist as stable episomal forms for long-term gene expression. 6 -8 However, the packaging capacity of recombinant AAVs is severely restricted owing to the small size of the viral genome; in addition, although integration of wt AAV DNA occurs in a site-specific manner, recombinant AAV vectors integrate randomly. 9, 10 An ideal stem cell vector would share the efficient delivery characteristics of the above viruses, but should also be capable of accommodating larger therapeutic genes and be able to maintain itself in a dividing cell population without the need for integration. Herpesviruses are large DNA viruses possessing genomes of between 100 and 250 kb. They are divided into ␣, ␤, and ␥ subgroups. Their advantages as gene therapy vectors relate to their ability to package large amounts of heterologous DNA and establish lifelong, latent infections in which the genomic material exists as a stable episome. Nearly all of the research in this field has focused on the use of herpes simplex virus (HSV) vectors for gene transfer to the nondividing cells of the nervous system. 11 One of the main reasons for this is that the HSV genome has no "latent-origin" of DNA replication, meaning that a state of episomal maintenance cannot be established in dividing cells. Another problem with HSV-based vectors is the likelihood of rapid clearance by the immune system owing to the endemic nature of the virus in the human population.
We are currently developing an alternative system, more suited to the requirements of stem cell gene therapy, based on herpesvirus saimiri (HVS). This virus is endemic in the Squirrel monkey population (Saimiri sciureus) and is the prototypic member of the ␥-2 herpesvirus genus (rhadinoviruses).
12,13 It also shows significant homology at the genomic level with the only known human member of the genus, human herpesvirus 8 or the Kaposi's sarcoma-associated herpesvirus. 14, 15 HVS strains have been subdivided into three groups (A, B, and C) on the basis of their oncogenic potential and the sequence of the open reading frame encoding the H. saimiri transformation-associated protein. 16, 17 Infection of human blood lymphocytes and thymocytes with strains of subgroup C, in contrast to the other subgroups, yields continuously proliferating T-cell lines. 18, 19 Earlier publications have demonstrated that a selectable HVS has the ability to persist in a variety of human cell lines for long periods of time, apparently without the production of infectious progeny. 20, 21 In this report, we describe our findings using a nontransforming wild-type (wt) virus carrying the enhanced green fluorescent protein (EGFP) and neomycin resistance (neo r ) marker genes. Using this vector, we have investigated tropism for specific lineages of hemopoietic cells, allowing us to elucidate potential strategies for clinical applications. We have also devised a protocol that substantially increases transduction efficiency and that may be generally applicable to other ex vivo gene therapy applications involving herpesviruses.
MATERIALS AND METHODS

HVS EGFP/NEO vector
The construction of the vector pJEGFPNeo and the virus HVS EGFP/NEO has been described elsewhere. 22 Briefly, pJEGFPNeo was constructed by inserting 1.8 kb of HVSA11 sequence from the 3Ј end of the genome, along with the cytomegalovirus immediate early (IE) promoter, into the HindIII site of the pEGFP-1 vector (Clontech, Palo Alto, Calif). This plasmid was inserted into the wtHVSA11 genome at a site spanning the junction between the unique and the repeat regions, via a single crossover event in the 3Ј 1. 
Cells and colony-forming unit (CFU)-Mix assay
All hemopoietic cell lines were grown in RPMI 1640 supplemented with 5% fetal calf serum (FCS), 100 U/mL penicillin, and 100 g/mL streptomycin (all from Life Technologies). In some experiments, HL60 cells were allowed to differentiate along the granulocytic lineage for 5 days with 1.25% dimethylsulfoxide (Life Technologies) or 1 M retinoic acid (Sigma, St. Louis, Mo), or along the monocytic lineage with 100 ng/mL phorbol myristate acetate (Sigma). Differentiation along the monocytic pathway was confirmed by morphology using Wright-Giemsa staining and nonspecific esterase staining.
Primary CD34 ϩ cells were isolated from human umbilical cord blood (HUCB). The CD34 ϩ fraction was positively selected from freshly isolated mononuclear cells (MNCs) using MiniMACS columns and a CD34 isolation kit (Miltenyi Biotec, Bisley, UK). CD34 ϩ cells were seeded at 10 3 cells/mL into a semisolid CFU-Mix assay in media consisting of 1.4% methylcellulose (Stem Cell Technologies, Vancouver, Canada), 26% FCS, 10% medium conditioned by the 5637 bladder carcinoma cell line, 2 U/mL erythropoietin (Boehringer Mannheim, Lewes, UK), 10 Ϫ4 M 2-mercaptoethanol (Life Technologies), and 1% bovine serum albumin (Sigma). Colonies were examined on day 14.
Primary CD14 ϩ cells were isolated from bone marrow MNCs using MiniMACS columns and CD14 ϩ microbeads (Miltenyi Biotec)
Transduction protocols
Unless otherwise stated, cells were infected using HVS EGFP/ NEO at a MOI of 20 using spinoculation and/or supernatant infection. Spinoculation involved the mixing of virus and 2 ϫ 10 5 cells in a total volume of 0.5 mL of medium followed by centrifugation at 1500 rpm for 90 minutes in a bench-top centrifuge. Supernatant infection involved the mixing of virus and cells in a minimal volume of medium followed by a 90-minute incubation at 37°C.
Fluorecent microscopy and flow cytometry
Expression of EGFP in the cells was detected using a Zeiss Axiovert microscope and Epics XL/MCL flow cytometer (Coulter Electronics, Luton, UK). The monoclonal antibodies CD34-PE (HPCA-2; Becton Dickinson, Fowley, UK) and CD14-PE (clone UCHM1; a kind gift of Dr. R. A. Jones, University of Leeds, Leeds, UK) were used for flow cytometry. Isotype-matched fluorescent controls were purchased from Serotec (Kidlington, UK). Fluorescent staining was carried out for 15 minutes at room temperature, followed by one wash with 1 mL of phosphate-buffered saline supplemented with 2% FCS and 0.1% NaN 3 (Sigma). In all experiments, propidium iodide (PI) (Sigma) at 4 g/mL was added to the cell samples before acquisition. Forward scatter/side scatter electronic gates were set up, and dead cells were gated out on the basis of PI positivity.
Episome analysis
Hirt extraction 22 was performed on 2 ϫ 10 6 Jurkat cells that had been grown in the presence or absence of 600 g/mL geneticin for 6 weeks; the episomal DNA was run on an 0.8% agarose gel at 5.5 V/cm for 11 hours in 1ϫ tris(hydroxymethyl)aminomethane borate ethylenediaminetetraacetic acid buffer and transferred to a nylon membrane. The Southern blot was then analyzed with 32 P-labeled probe, randomly primed from the plasmid pJEGFPNeo (i.e., the heterologous DNA contained within the recombinant virus).
RNA analysis
Cells were lysed using Trizol reagent (Life Technologies). Chloroform (0.2 mL) was then added, and the solution was vortex-mixed for 15 seconds and stored at room temperature for 5 minutes. Samples were centrifuged for 15 minutes at 4°C, and the aqueous phase containing nucleic acids was precipitated using 0.5 mL of isopropanol. The pellet was washed with 70% ethanol, resuspended in 20 L of diethyl pyrocarbonatetreated water (0.1% solution), and stored at Ϫ70°C. Northern blot analysis was performed essentially as described previously. 23 Total RNA was isolated from HVS-transduced Jurkat cells or from lytically infected OMK cells at 8, 16, 24, and 48 hours postinfection and separated by electrophoresis on 1% denaturing formaldehyde agarose gel. The RNA was transferred to Hybond-N membranes and hybridized with radiolabeled 32 P-labeled random primed probes made from restriction fragments derived from the HVS genome. Hybridizations were performed for 12 hours at 65°C using ExpressHyb buffer (Clontech).
Virus recovery assay
Infectious virus production was measured using two methods of virus recovery. First, supernatant was taken from a growing culture of HVS EGFP/NEO-transduced cells and used to infect 10 6 OMK cells. These cells are permissive for the growth of HVS, and the formation of plaques indicates the presence of infectious virus particles. In addition, the expression of EGFP by the recombinant virus allowed fluorescent microscopic analysis to determine whether any cells had been infected in a nonproductive manner. The negative control was nontransduced Jurkat cell supernatant, and the positive control was stably transduced SW480 cell supernatant (a human colonic cell line known to produce low levels of infectious virus particles). In the second method, the production and release of infectious virus particles into the supernatant of stably transduced Jurkat cells was measured by flow cytometry. Supernatant from the culture was collected and filtered using a 0. 
RESULTS
Construction of HVS EGFP/NEO virus
HVS EGFP/NEO was generated via a single crossover event between the recombination vector and the wt virus DNA (Fig 1) and has been described elsewhere. 22 Cells infected with this virus could be selected by the addition of geneticin to the medium and were easily identified by fluorescence microscopy or fluorescence-activated cell sorter analysis.
Comparison of spinoculation and supernatant infection in a range of hemopoietic cells Although the transduction of some human hemopoietic cell lines by HVS has been demonstrated previously, 20 nothing has been reported regarding the relative efficiencies with which various cell types can be transduced. Initial investigations were carried out using the standard method of supernatant infection and 12 different cell lines. Overall, there appeared to be no particular association between cell type and transduction efficiency, although mature B cells and early myeloid cells produced the lowest values. Three cell lines (Jurkat, THP-1, and U266) demonstrated the highest levels of transduction, with values of ϳ50% (Table 1) .
For gene therapy applications, it is also desirable to develop a general protocol to enhance the efficiency of transduction; we investigated a number of procedures, including the spinoculation technique. Table 1 illustrates the outcome of two separate experiments, carried out on nine of the cell lines, in which spinoculation was compared with the standard method of transduction. In all instances, spinoculation was superior, increasing efficiencies by Ͼ100% in a number of cases. However, it is also noteworthy that spinoculation only increased infectability to a point, with viral tropism being the main determinant.
Stable transduction of Jurkat cells
HVS is known to persistently infect cells by virtue of episomal maintenance of the virus genome. 20, 21 From the point of view of gene therapy, it is desirable to study this process in a quantitative manner, both in the presence and absence of selection. One of the most susceptible cell lines, Jurkat, was transduced with HVS EGFP/NEO and used to initiate cultures in the presence and absence of geneticin. After 2 days, 76% of the cells were found to express EGFP by flow cytometry. In keeping with published work, 21 geneticin-resistant clones were established that generated 100% EGFP ϩ cells by day 42, a figure which remained constant for the duration of the experiment (data not shown). In the absence of geneticin, the proportion of EGFP ϩ cells fell to 12.3% by day 42. Because the average length of time it took for a Jurkat cell to divide was measured as 29 hours (n ϭ 4), the retention of the EGFP phenotype can be calculated as Ͼ95% per division.
These data suggest that either the episomes were lost from the cells, the expression of EGFP was silenced by epigenetic effects, or EGFP mediated a toxic effect on the cells. To test these hypotheses, episomal DNA was extracted from Jurkat cells grown in the presence or absence of selection for 6 weeks by the Hirt method; next, the DNA was analyzed using a recombinant virusspecific probe and Southern blotting (Fig 2B) . DNA from identical numbers of cells was loaded in each lane, demonstrating that episomes were lost in the absence of Figure 3a shows a blot of stably transduced Jurkat cells and infected OMK cells that was probed for the ORF57 transcript (a major IE viral transactivator gene). 24 The same blot was also probed for glyceraldehyde-3-phosphate dehydrogenase as a loading control (Fig 3b) . Although the ORF57 transcript is abundant in infected OMK cells, it is totally absent from the Jurkat cell line. As a whole, these data demonstrated that the HVS infection of the Jurkat cell line was truly nonlytic in nature.
CD34
ϩ cell transduction and short-term colony assays
Hemopoietic stem cells and progenitors are contained within the CD34 ϩ fraction of blood; as such they represent attractive targets for gene therapy. 25 Several transductions of HUCB-derived CD34 ϩ cells were carried out using the spinoculation method and HVS EGFP/ NEO vector at a MOI of 100. The purity of CD34 ϩ fractions was confirmed using CD34-PE monoclonal antibody and was Ͼ95% in all experiments (n ϭ 4) (data not shown). Moreover, to determine the transduction of clonogenic progenitors within the CD34 ϩ fraction, parallel CFU-MIX cultures were established using uninfected and infected CD34 ϩ cells. Cultures were grown with or without geneticin for 14 days and examined thereafter for the presence of colonies.
An average of 9.9 Ϯ 5.7 EGFP ϩ cells were detected in Further analysis of HVS-infected CD34 ϩ cells revealed that the majority of EGFP ϩ cells (70 Ϯ 3%) were found in the CD34 low fraction of cells with high forward scatter/side scatter characteristics. As these cells were described as maturing myelomonocytic forms, 26 we proceeded with analysis of CD14 expression on the infected CD34 ϩ cells (Fig 4) . As seen in Figure 4B , 9.9% EGFP ϩ cells were detected in the whole fraction of CD34 ϩ cells in this experiment. When cells were gated on the basis of CD14 expression, 30.9% of cells expressed EGFP ( Fig  4D) . This confirmed a predominant HVS tropism toward more mature CD14 ϩ types within CD34 ϩ cells. We believe that infection of these cells resulted in the appearance of green nonclonogenic cells and small day 7 monocytic colonies in CFU-MIX experiments (data not shown). Similarly, inefficient transduction of more immature CD14
Ϫ cells resulted in a very low incidence of green day 14 colonies.
Although the CD14 molecule is expressed brightly on mature monocytes, a low level of expression is detected on both committed monocytic and granulocytic progenitors. 27 To test the hypothesis that HVS might have a monocytoid tropism, we used an HL60 differentiation model in which early myelomonocytic HL60 cells were driven into either granulocytic or monocytic differentiation using chemical substances. Cells were then transduced by HVS EGFP/NEO using spinoculation and analyzed for EGFP expression by flow cytometry. As seen in Table 2 , the efficiency of infection by HVS EGFP/NEO was increased up to 4-fold when HL60 cells acquired the monocytic phenotype. No improvement was detected when HL60 cells were differentiated into granulocytes.
To further confirm the theory that HVS may well have a tropism for CD14 ϩ cells, an assessment of infection efficiency in CD14 ϩ cells isolated from bone marrow MNCs was performed. Analysis by flow cytometry, gated on EGFP expression, revealed that 51.3% of the cells were successfully transduced (Fig 5) .
DISCUSSION
Stem cell gene therapy presents a combination of challenges that are currently not addressed by any single vector system. Multiple gene expression may be required in therapeutic settings and will be hard to achieve with retroviruses or AAVs due to their limited packaging capacities. In addition, integration into the human genome may lead to the rapid silencing of heterologous gene expression or even insertional mutagenesis (although this may not be of relevance in cancer gene therapy). HSV is capable of packaging multiple genes and delivering them to hemopoietic and DCs, 28 but expression is only transient because the genome is not replicated on cell division.
Another general obstacle to effective stem cell gene therapy is the low efficiency of transduction that is often observed with these primitive cell types. A number of elaborate methods have been developed to increase efficiency using other types of viral vectors. Examples include the use of flow-through transduction 29 or the colocalization of retrovirus and target cells on specific fibronectin fragments. 30 Reports have also described a technique termed "spinoculation" that improves the efficiency of retrovirus-mediated transduction. This involves the high-speed centrifugation of target cells with cell-free retrovirus supernatant. Although the mechanism by which efficiency is increased is not well understood, it is thought to increase the reversible binding of virus to cells. [31] [32] [33] As part of our initial investigations, we examined a number of different methods to improve the HVS-mediated transduction of human hemopoietic cell lines (data not shown). Of these, we found that a modified version of the spinoculation technique was most effective. This is a generally applicable, facile technique that can be used to markedly improve the efficiency of transduction for ex vivo gene therapy applications involving other herpesviruses.
The HVS vector used in these studies expressed EGFP 34 under the control of the cytomegalovirus IE promoter and expressed the neo r gene under the control of the simian virus 40 promoter. Virus-infected cells could thus be selected by the addition of geneticin to the culture medium and were also easily identifiable by fluorescence microscopy or flow cytometry. To investigate the maintenance of heterologous gene expression from the HVS genome in detail, Jurkat cells were infected with recombinant virus using the spinoculation technique and cultured in the presence and absence of geneticin for 6 weeks. After 48 hours, 72% of the cells were found to express EGFP by flow cytometry. In the absence of selection, levels of EGFP expression fell to ϳ12% over a 6-week period. This could be explained by a progressive loss of episome copy number, epigenetic silencing phenomena, or even a toxic effect of EGFP. Southern blot analysis of the comparative amounts of viral episomes showed that the absence of selection did indeed result in reduction over the 6-week period of the experiment. Assuming one round of cell division per day, this result demonstrated Ͼ95% retention of the EGFP phenotype (per division). Because the exact number of episomes in each cell was not known, this figure cannot be related directly to episome copy number. However this level of retention appears to compare favorably with Epstein-Barr virus-based systems, 35 which also exhibit episomal maintenance of the vector genome upon cell division.
Although we have previously demonstrated low levels of virus production at early times after infection in a wide variety of human cell lines transduced with HVS, 36 we were unable to detect any evidence of lytic virus growth in persistently infected Jurkat cells using a sensitive virus recovery assay. In addition, no transcripts of an abundant IE gene could be detected in the cell. As eluded to in our previous paper, this may be due to a shut-down of lytic replication over time. However, the need for the development of replication-disabled vectors remains paramount, and such vectors are currently being developed in our laboratory.
We have shown that HVS-based vectors can be used in gene transfer protocols involving multiple gene delivery to hemopoietic cells. Moreover, the fact that the virus genome was able to be maintained long-term through cell division suggests its possible use in applications for which nontransient delivery is crucial, such as the modification of primary hemopoietic progenitor cells. To investigate this, the spinoculation procedure was applied to HUCB CD34 ϩ cells, and an average efficiency of infection of 10% was achieved (comparable with retrovirus-based systems 25 ). However, when these cells were cultured in a CFU-MIX assay, the only green colonies appeared to be of macrophage-CFU (monocytic) lineage (data not shown). This result suggested that very few true stem cells were being transduced by HVS EGFP/NEO. Further analysis confirmed that the virus had a tropism for the monocytic lineage subpopulation of CD34 ϩ cells that also expressed CD14 (successfully transducing ϳ30%). In addition, the virus was shown to be capable of infecting CD14 ϩ cells, isolated from bone marrow, with an efficiency of 51.3%. Monocytic tropism was also tested by postdifferentiation transduction of the promyelocytic cell line HL60. Granulocytic lineage cells were transduced with an efficiency that was similar to ϩ cells were isolated from bone marrow MNCs using CD14 ϩ microbeads. Cells were infected using HVS EGFP/NEO at a MOI of 20 using the spinoculation protocol. Bold plot, infected cells; normal plot, uninfected cells.
that seen for undifferentiated cells, whereas monocytic lineage cells were transduced up to four times more efficiently. The reason for this difference is likely to be related to virus receptor proteins expressed on the cell surfaces, and is currently under investigation.
The combined abilities of the HVS vector system to efficiently deliver heterologous genes to monocytic lineage precursors and to be retained episomally on cell division suggest that it may be useful in cancer immunotherapy protocols. In addition, we have demonstrated recently that this virus is capable of infecting mouse embryonic stem cells and of maintaining heterologous gene expression in terminally differentiated macrophages. 22 This finding suggests that the virus may be useful in a range of progenitor cell-related applications.
Monocytic lineage precursors are known to give rise to DCs, the most potent Ag-presenting cells in the body and the only ones capable of priming naive cytotoxic T cells. 37, 38 Given their role in tumor immunity in vivo, 2 DCs constitute a highly attractive target for cancer gene therapy. Current strategies rely on the loading of mature DCs with tumor Ags 39 or on the delivery genes encoding tumor Ags to DCs using viral 40 and nonviral methods. 41 Delivery of tumor Ag cDNA to monocytic lineage progenitor cells by HVS vector may generate a genetic reservoir for a sustained response against the tumor. Clinically, the virus may be ideally suited to this task because of its ability to efficiently target monocytic precursors within the CD34 ϩ population without the need for additional purification steps before transduction.
